Cardiac amyloidosis is a rare disorder characterized by the abnormal deposition of amyloid proteins in the heart, leading to progressive heart failure.

The condition is often underdiagnosed due to its non-specific symptoms and the need for advanced diagnostic techniques. Early diagnosis and treatment are crucial for improving patient outcomes and quality of life. The increasing awareness about Cardiac Amyloidosis Market,  among healthcare professionals and the development of novel diagnostic and therapeutic approaches are expected to drive the growth of the market.

According To CoherentMI, the Global Cardiac Amyloidosis Market is estimated to be valued at USD 6.51 Bn in 2025 and is expected to reach USD 10.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Key Takeaways

Key players operating in the Cardiac Amyloidosis Market are Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Ionis Pharmaceuticals, Inc., and Prothena Corporation plc. These companies are actively involved in the development of novel therapies and diagnostic tools for cardiac amyloidosis. They are also focusing on collaborations and partnerships to expand their product portfolios and strengthen their market presence.

Get More Insights On: Cardiac Amyloidosis Market

Get this Report in Japanese Language: 心臓アミロイドーシス市場

Get this Report in Korean Language:  심장아밀로이드증시장-